These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29974058)

  • 1. Additively manufactured medical products - the FDA perspective.
    Di Prima M; Coburn J; Hwang D; Kelly J; Khairuzzaman A; Ricles L
    3D Print Med; 2016; 2():. PubMed ID: 29974058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomedical applications of tissue engineering technology: regulatory issues.
    Hellman KB
    Tissue Eng; 1995; 1(2):203-10. PubMed ID: 19877928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.
    Ionan AC; Clark J; Travis J; Amatya A; Scott J; Smith JP; Chattopadhyay S; Salerno MJ; Rothmann M
    Ther Innov Regul Sci; 2023 May; 57(3):436-444. PubMed ID: 36459346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory concerns in the development of biologic-biomaterial combinations. United States Food and Drug Administration.
    Chapekar MS
    J Biomed Mater Res; 1996; 33(3):199-203. PubMed ID: 8864892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualification of a non-animal vaginal irritation method admitted as nonclinical assessment model (NAM) in the Incubator Phase of the United States Food and Drug Administration (US FDA) Medical Devices Development Tool (MDDT).
    Costin GE; Hill E; Brown J; Clippinger AJ
    Toxicol In Vitro; 2020 Feb; 62():104680. PubMed ID: 31626901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine.
    Beitzel K; Allen D; Apostolakos J; Russell RP; McCarthy MB; Gallo GJ; Cote MP; Mazzocca AD
    J Knee Surg; 2015 Feb; 28(1):29-34. PubMed ID: 25268794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA working to ensure the safety of medical devices used in the pediatric population.
    Flack MN; Gross TP; Reid JS; Mills TT; Francis J
    Pediatr Clin North Am; 2012 Dec; 59(6):1355-66. PubMed ID: 23116531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regenerative Medicine Therapies for Rare Diseases.
    Lapteva L; Vatsan R; Purohit-Sheth T
    Transl Sci Rare Dis; 2018 Dec; 3(3-4):121-132. PubMed ID: 30613470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menstrual tampons and vaginal pessaries: regulation of intravaginal medical devices by the US FDA.
    Pollard CM
    Front Reprod Health; 2023; 5():1224421. PubMed ID: 37795520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration.
    Kuehn CM
    Biomedicines; 2019 Aug; 7(3):. PubMed ID: 31461892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D Printing to Support the Shortage in Personal Protective Equipment Caused by COVID-19 Pandemic.
    Tarfaoui M; Nachtane M; Goda I; Qureshi Y; Benyahia H
    Materials (Basel); 2020 Jul; 13(15):. PubMed ID: 32727050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing Regulatory Science With Computational Modeling for Medical Devices at the FDA's Office of Science and Engineering Laboratories.
    Morrison TM; Pathmanathan P; Adwan M; Margerrison E
    Front Med (Lausanne); 2018; 5():241. PubMed ID: 30356350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership.
    Johnson PC; Bertram TA; Carty NR; Hellman KB; Tawil BJ; Van Dyke M
    Tissue Eng Part A; 2014 Jun; 20(11-12):1565-82. PubMed ID: 24665855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing regulatory science to bring novel medical devices for use in emergency care to market: the role of the Food and Drug Administration.
    Scully CG; Forrest S; Galeotti L; Schwartz SB; Strauss DG
    Ann Emerg Med; 2015 Apr; 65(4):400-3. PubMed ID: 25128009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.